The global pharmaceutical market, now valued at roughly $1.7 trillion, continues to expand. With nearly $4.9 trillion spent annually on healthcare in the U.S. alone—half of the worldwide total—this isn’t just a sector driven by necessity; it’s one shaped by demographics, innovation, and enduring demand. Everyone needs healthcare, sooner or later, and when an entire industry grows significantly faster than the broader economy, long-term investors are wise to take notice.
But with thousands of publicly traded healthcare companies, how do you separate sustainable leaders from speculative stories? We’ve narrowed the field to six names spanning big pharma, medical devices, and next-generation gene editing—each positioned for 2026 and beyond.
There’s no sugarcoating it: Humira sales are in decline following its 2023 patent loss. But AbbVie saw this coming and prepared accordingly. Its successors, Skyrizi and Rinvoq, are already on track to surpass Humira’s peak annual sales combined in 2025. Meanwhile, oncology drugs Elahere and Venclexta continue gaining ground, and migraine treatments Qulipta and Ubrelvy are building strong market momentum.
For income investors, the dividend story is just as compelling. AbbVie is a Dividend King, having raised its payout for 50 consecutive years—with a 30%+ increase over just the past five. In an industry where patent cliffs claim many victims, AbbVie remains a case study in balancing pipeline execution with shareholder returns.
Ibrance, Xtandi, Eliquis, Prevnar—Pfizer still commands a portfolio of blockbusters. Yes, COVID products Comirnaty and Paxlovid have fallen off sharply, and several top sellers face patent expirations in the coming years. But Pfizer has been here before. The company has reinvested aggressively in R&D and struck key deals, most notably its 2023 acquisition of Seagen, fortifying its oncology franchise.
With 101 pipeline candidates—roughly one-third in late-stage testing or under regulatory review—Pfizer is restocking its arsenal. And for those seeking yield, its forward dividend remains among the highest in big pharma. It’s not a story of rebirth; it’s one of reinforcement.
For years, Vertex was synonymous with cystic fibrosis (CF) treatments. That identity is now outdated. The company, alongside CRISPR Therapeutics, secured U.S. approval for Casgevy in late 2023 and early 2024—a gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia. It also launched Journavx, an acute pain therapy, expanding beyond rare diseases into broader markets.
Vertex is no longer a single-indication story. It’s evolving into a multi-platform biotechnology company with both near-term revenue visibility and long optionality. In a sector where binary outcomes are the norm, Vertex offers rare balance.
Since its 1999 debut, the Da Vinci surgical system has been used in more than 17.6 million procedures. That number continues to accelerate. With the Ion endoluminal system, Intuitive Surgical has extended its reach into minimally invasive lung biopsy, opening a new frontier in early diagnosis.
But the real driver isn’t any single product—it’s demographics. An aging population requires precisely the types of procedures Da Vinci was built for: prostate, gynecologic, thoracic. Intuitive’s growth narrative isn’t about quarterly beats; it’s about procedural penetration over decades.
CRISPR hype has cooled, but the science hasn’t stopped. Beam stands out for its base-editing platform—a more precise tool that rewrites single letters of the genome without introducing double-strand breaks. Think genetic scissors versus a pencil with an eraser. In theory, this reduces the risk of unintended genomic rearrangements.
Beam is earlier stage than some peers, with Phase 1/2 programs targeting sickle cell disease, alpha-1 antitrypsin deficiency (AATD), and glycogen storage disease 1a (GSD1a). Its valuation reflects platform potential, not near-term revenue. For investors willing to look past volatility, Beam represents a differentiated bet within CRISPR.
CRISPR Therapeutics is the only pure-play gene-editing biotech with an approved product. Casgevy, developed in partnership with Vertex, received U.S. clearance for two indications in late 2023 and early 2024. Commercialization has begun.
The pipeline extends well beyond hematology. CTX112 and CTX131 are investigational CAR-T therapies targeting B-cell malignancies and solid tumors, respectively. CTX310 and CTX320 target cardiovascular disease; CTX211 is in development for type 1 diabetes. Preclinical work is exploring cystic fibrosis and Duchenne muscular dystrophy.
Thanks to its Vertex partnership and a fortified balance sheet, CRISPR Therapeutics carries less financing risk than most gene-editing peers. It’s still risky—but it’s the only one with a product on the market.
The hardest part of healthcare investing isn’t finding opportunities; it’s identifying companies that can survive patent cliffs, technological shifts, and regulatory cycles. These six stocks—spanning Dividend Kings, device incumbents, and CRISPR pioneers—offer distinct risk-return profiles for the year ahead. Whether each delivers on its 2026 narrative is a question worth following.
